Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Matsumoto Yushi-Seiyaku Co.,Ltd. (4365.T)
Yao, JP
Matsumoto Yushi-Seiyaku Co., Ltd., established in 1926 and headquartered in Yao, Japan, operates as a chemical enterprise with a presence in both Japan and Indonesia. The company specializes in the creation and distribution of a broad spectrum of chemical products, encompassing fiber and textile processing chemicals, microcapsules, various surfactants, and high-polymer-based compounds. Their offerings for the textile industry include spin finishes for extrusion and textile spinning, functional fiber surface treatments, sizing agents for weaving, lubricating oils for knitting and weaving machinery, and scouring and dyeing auxiliaries. Beyond textiles, they develop advanced materials such as thermo-expandable microcapsules, microbeads, and three-dimensional copying systems. For the rubber industry, they provide anti-tack powders and internal parting lubricants, while for plastics, they supply modifiers, antistatic agents, anti-fogging agents, and lubricants. The company also formulates ingredients for personal care items, including emulsifiers, base materials for shampoos and body soaps, fragrance solubilizing agents, and pearl-forming agents. Additionally, they produce chemicals for civil engineering and construction, alongside environmental conservation products designed for treating and defoaming nonionic surfactants. Matsumoto Yushi-Seiyaku's diverse product portfolio serves a wide array of sectors, such as information technology, electronics, automotive, precision instruments, construction, rubber, plastics, cosmetics, toiletries, and agriculture.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.96% | +1.71% | -0.51% | +4.70% | +7.01% | +8.48% | +22.46% | +50.71% | +105.68% | +132.28% | +349.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-4.8% Q1'26: +4.0% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+17.7% ★ Q1'26: +140.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+10.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+19.9% ★ Q1'26: +22.0% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+16.1% ★ Q1'26: +18.0% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroharu Kawahara | MD, Head of Sales & Export Department and Director | — | male |
| Naoki Kimura | Chief Executive Officer, President & Representative Director | — | male |
| Osaharu Fujii | Senior MD of Administrative Division & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4365.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
